Tweet
Does anyone know what the SOLiD 3plus upgrade entails?
-
-
<Original post Deleted since we haven't been through the 3+ upgrade yet>.
Notes from my co-worker (who was out at the recent SOLiD meeting): Not much of machine change this time, just a lower-profile flowcell. He also reports a 50% increase in beads per flowcell and that v.3 chemistry will run on the v.3.5 machines. -
This was discussed at length at the SOLiD User's summit last week. With respect to what Rick wrote, a new bead finding algorithm will allow a roughly 50% increase in the number of beads per flowcell. The recommended bead density will increase from 130-150 thousand beads/panel to 220 thousand beads/panel. Or from roughly 330 million raw reads/slide to 500 million.Originally posted by NextGenSeq View Post
This is accompanies a flowcell swap out, new slide carriers and a newly optimized sequence master mix. I remember there being a slight decrease in chemistry cost, although my guess is that it is more than counteracted by the extra ePCR that will be necessary to generate all those beads...
Perhaps more importantly a major secondary/tertiary software release will happen in "early November" called "BioScope v 1.0". Briefly, this package will replace Global SETS, but be free for SOLiD owners (unlike Global SETS). Mapping is said to be 3-10x faster and utilize a "seeded extension mapping" method that is said to successfully map 10-30% more reads.
The really crazy stuff seems to be in version 4, which is slated for "2010".
--
PhillipComment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment